Product
Pom/dex
Aliases
Pom/dex (Pomalidomide plus low dose Dexamethasone)
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)Status: Active (not recruiting), Estimated PCD: 2022-09-12